期刊
NEURODEGENERATIVE DISEASES
卷 7, 期 1-3, 页码 131-135出版社
KARGER
DOI: 10.1159/000289222
关键词
Alzheimer's disease biomarkers; PET neuroimaging; Early diagnostic tools; Amyloid lesions
资金
- Alzheimer's Disease Research Unit CIEN Foundation
- Reina Sofia Foundation, Madrid, Spain
- NATIONAL INSTITUTE ON AGING [R01AG022374, P30AG008051, R01AG013616] Funding Source: NIH RePORTER
Preclinical diagnosis of Alzheimer's disease (AD) is one of the major challenges for the prevention of AD. AD biomarkers are needed not only to reveal preclinical pathologic changes, but also to monitor progression and therapeutics. PET neuroimaging can reliably assess aspects of the molecular biology and neuropathology of AD. The aim of this article is to review the use of FDG-PET and amyloid PET imaging in the early detection of AD. Copyright (C) 2010 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据